For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE Ultra Human IFN-α Detection Kit is designed for detection and quantitation of human interferon α in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
The 500 point kit contains enough reagents to run 500 wells in 384-well format, using a 20 µL reaction volume (15 µL of sample). The 10,000 point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 µL reaction volume (15 µL of sample).
LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Interferon-alpha (IFN-α) is a cytokine involved in innate immune response against viral infection. It is produced by leukocytes and other cell types like plasmacytoid dendritic cells. There are many IFN-α subtypes, with molecular weights ranging from 15 to 21 kDa. They all possess the same antiviral activity, but may differ in their relative biological activities. IFN-α also exhibits several antiproliferative and antitumor activities, making it one of the most used cytokine treatments in cancer patients suffering from hairy cell leukemia, renal carcinoma, Kaposi’s sarcoma, and other malignancies. Under physiological conditions, a low level of IFN-α is detected. However, its production is markedly enhanced during infections and various pathological situations, making IFN-α a major disease marker.
|Assay Target Class||Cytokine|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Unit Size||10,000 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.